Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13890462 | 0.86 | CNR1 (0.40) | TSHRLMNAKMT2ACYP2D6THRB | |
| SCHEMBL8977510 | 0.84 | TSHR (0.61) | TSHRLMNAKMT2ACYP2D6PRKCA | |
| SCHEMBL12450820 | 0.84 | CNR1 (0.39) | TSHRLMNACA2 | |
| SCHEMBL12450812 | 0.81 | PTPN1 (0.56) | TSHRCYP2D6THRBHSD17B10CA2 | |
| SCHEMBL13875392 | 0.78 | CYP2D6 (0.48) | TSHRLMNAKMT2ACYP2D6PRKCA | |
| SCHEMBL2342815 | 0.76 | CYP2D6 (0.49) | TSHRLMNAKMT2ACYP2D6THRB | |
| SCHEMBL13875372 | 0.76 | CYP2D6 (0.49) | TSHRLMNAKMT2ACYP2D6THRB | |
| SCHEMBL23742930 | 0.74 | TSHR (0.64) | TSHRLMNAKMT2ACYP2D6PRKCA | |
| SCHEMBL15514610 | 0.74 | TSHR (0.64) | TSHRLMNAKMT2ACYP2D6PRKCA | |
| SCHEMBL8722654 | 0.74 | TSHR (0.64) | TSHRLMNAKMT2ACYP2D6PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513395-B2 | Method for the synthesis of anthocyanins | BIOSYNTH AS (NO) | 2013-08-20 | — | — | US | disclosed |
| US-8513395-B2 | Method for the synthesis of anthocyanins | BIOSYNTH AS (NO) | 2013-08-20 | — | — | US | disclosed |
| US-20090111975-A1 | METHOD FOR THE SYNTHESIS OF ANTHOCYANINS | BIOSYNTH AS (NO) | 2009-04-30 | — | — | US | disclosed |
| US-20090111975-A1 | METHOD FOR THE SYNTHESIS OF ANTHOCYANINS | BIOSYNTH AS (NO) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111975-A1 | METHOD FOR THE SYNTHESIS OF ANTHOCYANINS | POR, SPR, G6PD | TSHR 4373/4885LMNA 2745/4885KMT2A 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.